Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCZ | Q05513 | 9/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | KIF11 | P52732 | 1/20 | 0.46 |
| ▸ | PDE5A | O76074 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11068412 | 0.85 | MEN1 (0.54) | PRKCZATML3MBTL1EGFRPDE5A | |
| SCHEMBL908494 | 0.84 | CA1 (0.56) | PRKCZL3MBTL1EGFRPDE5ACA1 | |
| SCHEMBL11060811 | 0.84 | PRKCZ (0.56) | PRKCZATMEGFRPDE5AMAOA | |
| SCHEMBL11374953 | 0.83 | PRKCZ (0.53) | PRKCZATML3MBTL1EGFRMAOA | |
| SCHEMBL11095289 | 0.83 | PRKCZ (0.52) | PRKCZATML3MBTL1EGFRPDE5A | |
| SCHEMBL11089782 | 0.83 | ABL1 (0.46) | PRKCZATML3MBTL1EGFRPDE5A | |
| SCHEMBL11068397 | 0.80 | PRKCZ (0.52) | PRKCZEGFRPDE5A | |
| SCHEMBL11188275 | 0.80 | PRKCZ (0.56) | PRKCZL3MBTL1 | |
| SCHEMBL908054 | 0.79 | PRKCZ (0.45) | PRKCZ | |
| SCHEMBL11104257 | 0.77 | EGFR (0.57) | PRKCZATML3MBTL1EGFRPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003862-A1 | 3-Animopyraolines for Treatment of Neurodegenerative and Psychiatric Diseases | MERCK SHARP & DOHME LIMITED (GB) | 2011-01-06 | — | — | US | claimed |
| EP-1987007-A1 | 3-AMINOPYRAZOLINES FOR TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISEASES | MERCK SHARP & DOHME LTD. (GB) | 2008-11-05 | — | — | EP | claimed |
| WO-2007093829-A1 | 3-AMINOPYRAZOLINES FOR TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISEASES | MERCK SHARP & DOHME LIMITED (GB) | 2007-08-23 | — | — | WO | claimed |
| US-4451479-A | ANTIINFLAMMATORY | AMERICAN CYANAMID COMPANY (US) | 1984-05-29 | — | — | US | claimed |
| US-20110003862-A1 | 3-Animopyraolines for Treatment of Neurodegenerative and Psychiatric Diseases | MERCK SHARP & DOHME LIMITED (GB) | 2011-01-06 | — | — | US | disclosed |
| EP-1987007-A1 | 3-AMINOPYRAZOLINES FOR TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISEASES | MERCK SHARP & DOHME LTD. (GB) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093829-A1 | 3-AMINOPYRAZOLINES FOR TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISEASES | MERCK SHARP & DOHME LIMITED (GB) | 2007-08-23 | — | — | WO | disclosed |
| US-4451479-A | ANTIINFLAMMATORY | AMERICAN CYANAMID COMPANY (US) | 1984-05-29 | — | — | US | disclosed |
| EP-0070376-A1 | Heterocyclic substituted-amino-pyrazolines | AMERICAN CYANAMID COMPANY (US) | 1983-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003862-A1 | 3-Animopyraolines for Treatment of Neurodegenerative and Psychiatric Diseases | DAO, DDO, MAOA | PRKCZ 2127/4885ATM 797/4885L3MBTL1 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.